English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 10 Help

Selected(0)Clear Items/Page:    Sort:
Editorial: New mechanistic insights into cancer precision medicine Other
2023-02-16
Authors:  Kwok,Hang Fai
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date：2023/08/03
Immunotherapy  Targeted Therapy  Therapeutic Antibody  Chemotherapy  Novel Bioactive Molecule  Biomarker  Drug Resistance  
A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis Journal article
Li, Junnan, Chen, Pengchen, Wu, Qiushuang, Guo, Libin, Leong, Ka Weng, Chan, Kin Iong, Kwok, Hang Fai. A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis[J]. Cellular and Molecular Life Sciences, 2022, 79(12), 614.
Authors:  Li, Junnan;  Chen, Pengchen;  Wu, Qiushuang;  Guo, Libin;  Leong, Ka Weng; et al.
Favorite | TC[WOS]:7 TC[Scopus]:6  IF:6.2/7.7 | Submit date：2023/01/30
Antibody Therapy  Cell Death  Drug Target  Precision Oncology  Small Molecule  
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy Journal article
Lu, Dan, Xu, Zepeng, Zhang, Ding, Jiang, Min, Liu, Kefang, He, Juanhua, Ma, Dongli, Ma, Xiaopeng, Tan, Shuguang, Gao, George F., Chai, Yan. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy[J]. Frontiers in Immunology, 2022, 13, 826045.
Authors:  Lu, Dan;  Xu, Zepeng;  Zhang, Ding;  Jiang, Min;  Liu, Kefang; et al.
Favorite | TC[WOS]:22 TC[Scopus]:24  IF:5.7/6.8 | Submit date：2022/04/06
Antibody  Cemiplimab  Immune Checkpoint Therapy (Ict)  N58 Glycosylation  Pd-1  
Natural Products in Cancer Therapy: Past, Present and Future Journal article
Huang,Min, Lu,Jin Jian, Ding,Jian. Natural Products in Cancer Therapy: Past, Present and Future[J]. Natural Products and Bioprospecting, 2021, 11(1), 5-13.
Authors:  Huang,Min;  Lu,Jin Jian;  Ding,Jian
Favorite | TC[WOS]:324 TC[Scopus]:333  IF:4.8/3.9 | Submit date：2021/03/02
Antibody–drug Conjugates  Cancer Therapy  Combination Therapy  Drug Discovery  Natural Products  
Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo Conference paper
Ye, Jie, Yuen, Shun Ming, Murphy, Gillian, Xie, Ruiyu, Kwok, Hang Fai. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo[C], PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS:ELSEVIER SCIENCE BV, 2017, 62-69.
Authors:  Ye, Jie;  Yuen, Shun Ming;  Murphy, Gillian;  Xie, Ruiyu;  Kwok, Hang Fai
Favorite | TC[WOS]:22 TC[Scopus]:23 | Submit date：2018/10/31
Pancreatic Ductal Adenocarcinoma (Pdac)  Adam17  Inhibitory Antibody  Tumorigenesis  Targeted Therapy  
Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo Journal article
Ye J., Yuen S.M., Murphy G., Xie R., Kwok H.F.. Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo[J]. European Journal of Pharmaceutical Sciences, 2017, 110, 62-69.
Authors:  Ye J.;  Yuen S.M.;  Murphy G.;  Xie R.;  Kwok H.F.
Favorite | TC[WOS]:22 TC[Scopus]:23  IF:4.3/4.2 | Submit date：2018/12/19
Adam17  Inhibitory Antibody  Pancreatic Ductal Adenocarcinoma (Pdac)  Targeted Therapy  Tumorigenesis  
Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 Journal article
Ye, J., Yuen, S. M., Murphy, G., Xie, R., Kwok, H. F.. Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17[J]. European Journal of Pharmaceutical Sciences, 2017, 62-69.
Authors:  Ye, J.;  Yuen, S. M.;  Murphy, G.;  Xie, R.;  Kwok, H. F.
Favorite |   IF:4.3/4.2 | Submit date：2022/06/02
Pancreatic Ductal Adenocarcinoma (Pdac)  Adam17  Inhibitory Antibody  Tumorigenesis  Targeted Therapy  
Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3 Journal article
Ahmed, M, Cheng, M, Zhao, Q., Goldgur, Y, Cheal, S, Guo, HM, Larson, S, Cheung, N. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3[J]. Journal of Biological Chemistry, 2015, 30018-30029.
Authors:  Ahmed, M;  Cheng, M;  Zhao, Q.;  Goldgur, Y;  Cheal, S; et al.
Favorite |   IF:4.0/4.4 | Submit date：2023/08/30
Antibody engineering  cancer therapy  homology modelling  immunotherapy  molecular docking  
Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy Journal article
Ling L., Tan S.K., Goh T.H., Cheung E., Nurcombe V., van Wijnen A.J., Cool S.M.. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy[J]. Molecular Cancer, 2015, 14(1).
Authors:  Ling L.;  Tan S.K.;  Goh T.H.;  Cheung E.;  Nurcombe V.; et al.
Favorite | TC[WOS]:18 TC[Scopus]:19  IF:27.7/31.3 | Submit date：2018/12/17
Cell Death  Cell Growth  Heparan Sulfate  Neutralizing Antibody  Targeted Therapy  Tumor  
Alteration of electrostatic surface potential enhances affinity and tumor killing properties of anti-ganglioside GD2 monoclonal antibody hu3F8 Journal article
Zhao, Q., Ahmed, M., Guo, H., Cheung, I., Cheung, N.. Alteration of electrostatic surface potential enhances affinity and tumor killing properties of anti-ganglioside GD2 monoclonal antibody hu3F8[J]. Journal of Biological Chemistry, 2015, 13017-13027.
Authors:  Zhao, Q.;  Ahmed, M.;  Guo, H.;  Cheung, I.;  Cheung, N.
Favorite |   IF:4.0/4.4 | Submit date：2023/08/30
antibody engineering  cancer therapy  electrostatics  ganglioside  immunotherapy